journal article·2024-06

Synergistic effects of photodynamic therapy and chemotherapy: Activating the intrinsic/extrinsic apoptotic pathway of anoikis for triple-negative breast cancer treatment

Tianyu Zhang, Xueyuan Wang, Dongna Wang, Meng Lei, Yixue Hu, Zhimeng Chen, Yuting Li, Yingnan Luo, Liefeng Zhang, Yongqiang Zhu

Publisher page

Abstract

Triple-negative breast cancer (TNBC) is a highly invasive and metastatic subtype of breast cancer that often recurs after surgery. Herein, we developed a cyclodextrin-based tumor-targeted nano delivery system that incorporated the photosensitizer chlorin e6 (Ce6) and the chemotherapeutic agent lonidamine (LND) to form the R6RGD-CMβCD-se-se-Ce6/LND nanoparticles (RCC/LND NPS). This nanosystem could target cancer cells, avoid lysosomal degradation and further localize within the mitochondria. The RCC/LND NPS had pH and redox-responsive to control the release of Ce6 and LND. Consequently, the nanosystem had a synergistic effect by effectively alleviating hypoxia, enhancing the production of cytotoxic reactive oxygen species (ROS) and amplifying the efficacy of photodynamic therapy (PDT). Furthermore, the RCC/LND NPS + light weakened anoikis resistance, disrupted extracellular matrix (ECM), activated both the intrinsic apoptotic pathway (mitochondrial pathway) and extrinsic apoptotic pathway (receptor death pathway) of anoikis. In addition, the nanosystem showed significant anti-TNBC efficacy in vivo. These findings collectively demonstrated that RCC/LND NPS + light enhanced the anticancer effects, induced anoikis and inhibited tumor cell migration and invasion through a synergistic effect of chemotherapy and PDT. Overall, this study highlighted the promising potential of the RCC/LND NPS + light for the treatment of TNBC.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (46)

Show source-provided references
1. Economic and humanistic burden of triple-negative breast cancer: a systematic literature review10.1007/s40273-021-01121-7 ↗
2. Lovastatin inhibits EMT and metastasis of triple-negative breast cancer stem cells through dysregulation of cytoskeleton-associated proteins
3. Targeting hypoxia-inducible factor-1alpha: a new strategy for triple-negative breast cancer therapy10.1016/j.biopha.2022.113861 ↗
4. From interaction to intervention: how mesenchymal stem cells affect and target triple-negative breast cancer10.3390/biomedicines11041182 ↗
5. Mechanisms of resistance of chemotherapy in earlystage triple negative breast cancer (TNBC)10.1016/j.breast.2017.06.023 ↗
6. Definition of type I and type II photosensitized oxidation10.1111/j.1751-1097.1991.tb02071.x ↗
7. Hypoxia-dependent inhibition of tumour cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells10.4049/jimmunol.1101011 ↗
8. H2O2-responsive polymer prodrug nanoparticles with glutathione scavenger for enhanced chemo-photodynamic synergistic cancer therapy
9. Periodic mesoporous organosilica coupled with chlorin e6 and catalase for enhanced photodynamic therapy to treat triple-negative breast cancer10.1016/j.jcis.2021.11.107 ↗
10. Unimolecular photodynamic O2-economizer to overcome hypoxia resistance in phototherapeutics10.1021/jacs.0c00734 ↗
11. Construction of a near-infrared responsive upconversion nanoplatform against hypoxic tumors via NO-enhanced photodynamic therapy10.1039/C9NR10453D ↗
12. Conquering the hypoxia limitation for photodynamic therapy10.1002/adma.202103978 ↗
13. Microenvironmental control of cell fate decisions in mammary gland development and cancer10.1016/j.devcel.2021.06.016 ↗
14. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)10.1016/j.breast.2017.06.023 ↗
15. Nanopurpurin-based photodynamic therapy destructs extracellular matrix against intractable tumor metastasis10.1016/j.biomaterials.2018.04.045 ↗
16. Modulating cancer-stroma crosstalk by a nanoparticle-based photodynamic method to pave the way for subsequent therapies10.1016/j.biomaterials.2022.121813 ↗
17. Use of cyclodextrins in anticancer photodynamic therapy treatment10.3390/molecules23081936 ↗
18. Effective drug and shRNA delivery for synergistic treatment of triple-negative breast cancer by sequentially targeting tumor hypoxia10.1016/j.cej.2023.144271 ↗
19. Mechanisms for modulating anoikis resistance in cancer and the relevance of metabolic reprogramming10.3389/fonc.2021.626577 ↗
20. Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis10.1007/s00432-013-1482-5 ↗
21. Effect and mechanism of action in vitro of cyclodextrin derivative nanoparticles loaded with tyroserleutide on hepatoma10.1088/1361-6528/abf3f2 ↗
22. Reactive oxygen species and folate receptor-targeted nanophotosensitizers composed of folic acid-conjugated and poly(ethylene glycol)-chlorin e6 tetramer having diselenide linkages for targeted photodynamic treatment of cancer cells10.3390/ijms23063117 ↗
23. Redox-sensitive and folate-receptor-mediated targeting of cervical cancer cells for photodynamic therapy using nanophotosensitizers composed of chlorin e6-conjugated beta-cyclodextrin via diselenide linkage10.3390/cells10092190 ↗
24. Smart nanomaterials for cancer diagnosis and treatment10.1186/s40580-022-00313-x ↗
25. Disrupting the redox balance with a diselenide drug delivery system: synergistic or antagonistic?10.1002/adfm.202007275 ↗
26. In situ diselenide-crosslinked polymeric micelles for ROS-mediated anticancer drug delivery10.1016/j.biomaterials.2016.06.044 ↗
27. The photostability and fluorescence properties of diphenylisobenzofuran10.1016/j.jlumin.2011.05.048 ↗
28. Alpha(v)beta(3) integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo10.2147/IJN.S146505 ↗
29. Biological properties of arginine-rich peptides and their application in cargo delivery to cancer
30. Cationic arginine-rich peptides (CARPs): a novel class of neuroprotective agents with a multimodal mechanism of action10.3389/fneur.2020.00108 ↗
31. New strategy for precise cancer therapy: tumor-specific delivery of mitochondria-targeting photodynamic therapy agents andin situO2-generation in hypoxic tumors10.1039/D0BM00500B ↗
32. Anoikis resistance––protagonists of breast cancer cells survive and metastasize after ECM detachment10.1186/s12964-023-01183-4 ↗
33. Live free or die: tales of homeless (cells) in cancer10.2353/ajpath.2010.091270 ↗
34. Inhibition of mitochondrial complex II by the anticancer agent lonidamine10.1074/jbc.M115.697516 ↗
35. Anthracene-based fluorescent MOFs decorated by platinum nanozymes as a multifunctional nanoplatform for enhanced photodynamic therapy and self-monitoring of real-time singlet oxygen10.1016/j.cej.2022.137333 ↗
36. Manganese superoxide dismutase promotes anoikis resistance and tumor metastasis10.1038/cddis.2013.20 ↗
37. Manganese superoxide dismutase mediates anoikis resistance and tumor metastasis in nasopharyngeal carcinoma10.18632/oncotarget.8717 ↗
38. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition10.1038/emboj.2010.351 ↗
39. Connective tissue growth factor (CTGF) and cancer progression10.1007/s11373-008-9264-9 ↗
40. The role of YAP1 target gene CTGF in the anoikis resistance of rheumatoid arthritis synovial fibroblasts10.1093/rheumatology/keac354 ↗
41. Hypoxia-inducible factor 1 alpha mediates anoikis resistance via suppression of alpha 5 integrin10.1158/0008-5472.CAN-08-1839 ↗
42. Lactate is always the end product of glycolysis10.3389/fnins.2015.00022 ↗
43. Regulation of cancer cell metabolism10.1038/nrc2981 ↗
44. 2-Deoxy-D-glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype10.1038/s41598-019-39789-9 ↗
45. Extracellular matrix structure10.1016/j.addr.2015.11.001 ↗
46. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane10.1128/MCB.20.3.929-935.2000 ↗